- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Praveen Thadani of Priority Health Receives Annual Bernard J. Tyson Health Equity Award
Praveen Thadani, president of Priority Health, has been recognized for his tireless work at reducing health care disparities over a 25-year career with the 2022 Bernard J. Tyson Health Equity Award.
Grand Rapids, Michigan — The Bernard J. Tyson Health Equity Award, established in 2021, has been given this year to Praveen Thadani, president of Priority Health. It was awarded by the Alliance of Community Health Plans.
The annual award honors the late Bernard J. Tyson, former chairman and CEO of Kaiser Permanente, and this year it recognizes Thadani for his career-spanning dedication to increasing health equity and addressing coverage and care disparities among all Americans. He joined Priority Health in 2021.
“I am honored and truly grateful that the good work of Priority Health is being recognized,” said Thadani. "We believe the only way to make a real impact on our communities is to focus on what is at the root of health inequities, like the social determinants of health. We all have the right to live our best lives regardless of the circumstances to which we are born, live, work and age.”
Employers Shift to Equity-Focused Strategies as Health Costs Outpace Wages
October 31st 2024As health care costs escalate, a new survey reveals that 74% of employers are grappling with the impact on employee wages and benefits, with many anticipating further cost-shifting to their workforce.
Read More
Sustaining Compassionate Trauma Care Across Communities
September 30th 2024September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In our final episode, we speak with Lyndra Bills, MD, and Shari Hutchison, MS.
Listen
Targeting Progression: Amivantamab’s Role in NSCLC After Osimertinib
October 24th 2024Amivantamab's role in non–small cell lung cancer (NSCLC) has been a highlight of the lung cancer space this year, with the 2 most recent approvals based on data from the MARIPOSA and MARIPOSA-2 trials.
Read More
